Regulatory Considerations to Accelerate Cell & Gene Therapy Development

Jiwen Zhang, Ph.D.

Cellicon Valley 2021, May 6, 2021
Disclaimer

The views, thoughts, and opinions expressed in the presentation belong solely to the speaker, and not necessarily to the speaker's employer, organization, committee or other group or individual.
Outline

• Global landscape for cell and gene therapy products
• Development challenges, uncertainties
• Regulatory considerations to accelerate product development
• It takes a village: stake holder initiatives
• Dynamic landscape with challenges, uncertainties
Recent Approvals in Global Market

- Libmeldy (Orchard Tx) – Europe
- Tecartus (Kite, a Gilead company) – US
- Zolgensma (Novartis Gene Therapies) – Europe, Japan, Canada
- Luxturna (Spark / Roche) – Canada
- Abecma (Celgene/BMS) – US

US FDA approved products

Approved Cellular and Gene Therapy Products | FDA
Clinical Trials by Indication

- Oncology: 554
- Central nervous system: 94
- Monogenetic diseases: 87
- Infectious disease: 73
- Cardiovascular: 66
- Hematological: 57
- Musculoskeletal: 54
- Ophthalmology: 51
- Immunology: 39
- Metabolic disorders: 37
- Gastroenterology: 32
- Genitourinary & Sex Hormones: 25
- Dermatology: 24
- Respiratory: 20
- Other: 7

1,220 ONGOING REGENERATIVE MEDICINE & ADVANCED THERAPY TRIALS WORLDWIDE

The late-stage clinical pipeline continued to advance.
Regulations, guidelines – 2021 highlights

• Spain: AEMPS authorises Hospital Clínic's CAR-T ARI-0001 for patients with acute lymphoblastic leukaemia (clinicbarcelona.org) – Feb’21
• Singapore’s new regulations for cell, tissue and gene therapy products HSA | CTGTP – March’21

• FDA/CBER/OTAT 2021: Guidance Agenda: Guidance Documents CBER is Planning to Publish During Calendar Year 2021 (fda.gov)
Challenges, Uncertainties …

- Manufacturing capacity can not keep up with demand
- CMC often behind accelerated clinical development
- Early biomarker response may or may not predict clinical benefits
- There are still a lot of unknowns in terms of safety
- Regulatory standards are evolving as science and technology advance; regulatory requirements vary across countries, regions
• Regulatory considerations to accelerate development
Follow Regulatory Guidance

- Understand intent
- Recognize ambiguity, flexibility
- Determine appropriate requirements

- US FDA: Cellular & Gene Therapy Guidances | FDA
  - Guidance Agenda: Guidance Documents CBER is Planning to Publish During Calendar Year 2021 (fda.gov)

- EU EMA: Guidelines relevant for advanced therapy medicinal products | European Medicines Agency (europa.eu)

- Japan PMDA: Regulatory Science/The Science Board/Standard Development | Pharmaceuticals and Medical Devices Agency (pmda.go.jp)

- Health Canada: Guidance documents - Biologics, Radiopharmaceuticals and Genetic Therapies - Canada.ca
Consult with Agencies: Early, Frequent, Well Planned

<table>
<thead>
<tr>
<th>Milestone Meetings</th>
<th>Information Meetings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>US FDA</strong></td>
<td><strong>US FDA</strong></td>
</tr>
<tr>
<td>• Pre-IND, EOP2, pre-BLA/NDA</td>
<td>• INTERACT for RMAT – pre-pre IND</td>
</tr>
<tr>
<td><strong>EMA</strong></td>
<td><strong>UK</strong></td>
</tr>
<tr>
<td>• CHMP Scientific Advice</td>
<td>• Broader scope meeting</td>
</tr>
<tr>
<td><strong>Japan</strong></td>
<td><strong>Brazil</strong></td>
</tr>
<tr>
<td>• PMDA consultations on quality, nonclinical, clinical, Cartagena protocol for gene therapy</td>
<td>• Information meeting</td>
</tr>
<tr>
<td><strong>National agencies</strong></td>
<td>Consult local regulatory experts for country specific meeting types, formats, procedures, &amp; timelines</td>
</tr>
<tr>
<td>• Pre-CTA/submission meetings</td>
<td></td>
</tr>
</tbody>
</table>

Agency consultations are key components of regulatory strategy to de-risk development programs.
### Conventional mechanisms
- Intent to expedite drug development to treat serious conditions
- Frequent agency interactions
- May accept surrogate efficacy endpoints
- Criteria dictates when to request
- Fast Track (FT)
- Breakthrough (BT)

### Cell & gene specific mechanisms
- Similar intent and concept as conventional mechanisms
- Specific regulatory framework and oversight for cell & gene products
- Take consideration of cell gene specific challenges and transformative nature
- Regenerative Medicine Advanced Therapy (RMAT)

### Rare disease related
- Intent to encourage drug development to treat rare diseases
- Incentives more commercial or financial oriented
- Serious nature of the rare diseases often eligible for other reg mechanisms
- Orphan drug designation (ODD)
## Comparison of US and EU Regulatory Mechanisms

<table>
<thead>
<tr>
<th>US</th>
<th>EU</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fast Track (FT)</strong></td>
<td><strong>PRIME Scheme</strong></td>
</tr>
<tr>
<td><strong>Breakthrough Therapy (BT)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Regenerative Medicine Advanced Therapy (RMAT)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Priority Review</strong></td>
<td><strong>Accelerated Assessment</strong></td>
</tr>
<tr>
<td><strong>Accelerated Approval (based on surrogate or intermediate endpoints)</strong></td>
<td><strong>Conditional MAA (based on less complete clinical data)</strong></td>
</tr>
<tr>
<td><strong>(no equivalent)</strong></td>
<td><strong>Approval under Exceptional Circumstances</strong></td>
</tr>
<tr>
<td><strong>Expanded Access</strong></td>
<td><strong>Compassionate Use Early Access Schemes</strong></td>
</tr>
</tbody>
</table>

### Kymriah regulatory designations & pathways

**US:**
- **Designations:** FT, BT, RMAT (2020); Orphan, Rare Pediatric Disease
- **Full approval (2017)**

**EU:**
- **Designations:** PRIME; Orphan
- **Full approval (2018)**

Zolgensma: conditional approval in EU with a broader indication than US

Courtesy of NDA Group
“If there is sufficient evidence that the safety and effectiveness of the RMAT would not be compromised when administered with the identified general class or specific subset of delivery devices, the RMAT could be approved with more general labeling rather than specifying a particular delivery device.”

Luxturna approach – FDA Reviewer’s comments:

- The applicant also notes that biocompatibility using Medallion® 1-mL syringe hasn’t been tested because like the 1 ml Becton and Dickinson syringe, the Medallion® 1-mL syringe 510(k) # K875196 (Merit Medical Systems, Inc) mentioned in the surgical (b) (4) (b) (4) (b) (4) 113 manual, is an alternative to 1mL BD syringe and is manufactured using similar polycarbonate material. This is acceptable.

- The applicant also notes that Spark does not propose to limit the device components to any specific brand because of the use of P188 in the formulation and because of the compatibility data generated to date. This is acceptable as there tends to be little variation in the materials used for ophthalmic instruments among various device manufacturers.
• It takes a village
Stake Holder Initiatives

- **Global regulatory convergence** - “FDA and EMA signal an opportunity to harmonize advanced therapy regulations”

- **Good Regulatory Practices & Good Reliance Practices (WHO Expert Committee Report 2021):**
  https://apps.who.int/iris/bitstream/handle/10665/340323/9789240020900-eng.pdf
  “The purpose of the **Good Reliance Practices** is to promote a more efficient approach to regulation, thereby improving access to quality-assured, effective and safe medical products. Reliance allows leveraging the output of others whenever possible while placing a greater focus at national level on value-added regulatory activities.”

- **ARM/industry** initiatives on accelerating CMC development

- Developing and implementing standards for Regen Med products

- Patient engagement in cell and gene therapy development
- Natural history data as external control to support product registration
  - …